



All

Images

Videos

翻译成中文

关闭取词

2,740 Results

Any time ▾

PD-0029CHEMOTHERAPY PLUS CETUXIMAB AS ...

https://academic.oup.com/annonc/article/24/suppl_4/... ▾

Mobile Microsite Search Term. Sign In . Register

Targeted Therapies in Metastatic Colorectal Cancer: A ...

theoncologist.alphamedpress.org/content/19/11/1156.long

Nov 01, 2014 · **Cetuximab** is effective with **fluoropyrimidine**, leucovorin, and irinotecan (FOLFIRI) in **first-line settings** and as a single agent in **last-line settings**. Efficacy for panitumumab has been shown with oxaliplatin with **fluoropyrimidine** in **first-line settings**, with FOLFIRI in second-line settings, and as monotherapy in last-line settings.

Author: Martha M. Kirstein

Published

in: **Oncologist** · 2014**Authors:** Martha M Kirstein · A Lange · Anne Prenzler · Michael P Manns · S Kubicka · Arndt V...**Affiliation:** Hannover Medical School

About:

Cetuximab · Fluorouracil · Panitumumab · Regorafenib · Organoplatinum Compounds

S-1 plus Raltitrexed for Refractory Metastatic Colorectal ...

theoncologist.alphamedpress.org/lookup/resid/24/5/591?view=full&urtype=cgi

The Oncologist is a journal devoted to medical and practice issues for surgical, radiation, and medical oncologists.

Author: Ye Chen

Cost-Effectiveness Analysis of Regorafenib for Third-line ...

health-medical-economics.imedpub.com/costeffectiveness-analysis-of-regorafenib-for... ▾

Jul 13, 2018 · The **survival data** for the combination therapy **cetuximab** plus irinotecan was obtained from a single **arm trial** of patients with **mCRC** previously exposed to **fluoropyrimidine**, irinotecan and oxaliplatin containing **regimes**. The **median PFS** and **OS** for patients with **mutation biomarkers** were 4.2 and 8.6 months, respectively.

Cited by: 1**Author:** Shuiqing Zhu, Jin Liu, Wentao Sun, Lib...**Publish Year:** 2018

Cetuximab Publications | PubFacts

<https://www.pubfacts.com/search/Cetuximab/1> ▾

Aim: The open-label, nonrandomized, phase II APEC study enrolled 167 patients with **RAS wild-type (wt) metastatic colorectal cancer (mCRC)** to investigate the safety and efficacy of first-line, every-2-weeks **cetuximab** plus investigator's choice of FOLFIRI or FOLFOX in this patient population.

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population

Ka-On Lam, Man-Chi Fu, Kin-Sang Lau, Kam-Mo Lam, Cheuk-Chiu, Cheng-Man Yuen, Lai-Han Kwok, Fong-Kit Tam, Wai-Chan, Pui-Ying Ho, To-Wai Leung, Ho-Fun Lee

Abstract

BACKGROUND

Cetuximab in combination with oral fluoropyrimidine (FP) for metastatic colorectal cancer (mCRC). In view of the good tolerability of FP, we conducted a retrospective analysis to compare the efficacy and safety profile of cetuximab in combination with oral FP in Chinese population in the real-world setting.

AIM

To compare the efficacy and safety profile of cetuximab in combination with oral FP in Chinese population in the real-world setting.

METHODS

A retrospective cohort study was done to analyse consecutive type mCRC who received first-line treatment with cetuximab and chemotherapy in our unit from January 2010 to December 2018. The median follow-up of our cohort was 12.5 months.

RESULTS

The median progression-free survival (mPFS) and median overall survival (OS) of the entire cohort were 9.66 mo (95% CI = 7.72–12.5) and 25.8 mo (95% CI = 15.2–36.3), respectively. Between oral FP and infusional FP, there was no significant difference in the mPFS (9.79 mo [95% CI = 7.49–12.7] vs 9.63 mo [95% CI = 7.49–12.7], $P = 0.72$) and OS (25.8 mo [95% CI = 15.2–36.3] vs 26.2 mo [95% CI = 15.2–36.3], $P = 0.72$).

Match Overview

1	Internet 33 words crawled on 29-Nov-2015 sisterindo.org	1%
2	Internet 31 words crawled on 03-Dec-2018 www.sabcs.org	1%
3	Internet 29 words crawled on 27-Jul-2019 cslide.ctimeetingtech.com	1%
4	Internet 22 words crawled on 21-Jul-2019 www.oncotarget.com	1%
5	Internet 21 words crawled on 12-Aug-2019 accpjournals.onlinelibrary.wiley.com	1%
6	Internet 21 words crawled on 21-Jun-2019 bmccancer.biomedcentral.com	1% 
7	Internet 19 words crawled on 13-Aug-2019 mafiadoc.com	1%
8	Crossref 18 words Line S. Tarpgaard, Ib J. Christensen, Gunilla Høyer-Hansen, Ida K. Lund et al. "Intact and cleaved plasma soluble	1%
9	Internet 18 words crawled on 01-Oct-2016 f1000.com	1%
10	Internet 17 words crawled on 07-May-2019 www.nice.org.uk	<1%

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Re



All

Images

Videos

翻译成中文

关闭取词

10,500 Results

Any time ▾

Cetuximab Monotherapy and Cetuximab plus Irinotecan in ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa033025>

Jul 22, 2004 - A phase 2 study of weekly cetuximab and irinotecan in 121 patients who had colorectal cancer that was refractory to fluorouracil and irinotecan found a 17 percent response rate. 17 In a ...

Cited by: 5651

Author: David Cunningham, Yves Humblet, Salvat...

Publish Year: 2004

PD-0029CHEMOTHERAPY PLUS CETUXIMAB AS ...

https://academic.oup.com/annonc/article/24/suppl_4/iv35/151730 ▾

Jun 01, 2013 - Search terms were: cetuximab, metastatic colorectal cancer, KRAS, colorectal metastases, resection, and clinical study. Duplicates were removed by an automated process. Results were checked for relevance regarding the inclusion of data related to liver-limited disease.

Cited by: 2

Author: Eric Van Cutsem, Gunnar Folprecht, Cars...

Publish Year: 2013

Author: Van Cutsem, Eric

S-1 plus Raltitrexed for Refractory Metastatic Colorectal ...

theoncologist.alphamedpress.org/content/24/5/591.full

May 01, 2019 - 5-fluorouracil (5-FU) is a fundamental drug in the treatment of metastatic colorectal cancer (mCRC). Patients with mCRC are often exposed to 5-FU and/or its analogues for a long time because of its central role in treatment regimens.

Cited by: 1

Author: Ye Chen, Jing Wu, Ke Cheng, Zhi-Ping Li...

Publish Year: 2019

Author: Ye Chen

Targeted Therapies in Metastatic Colorectal Cancer: A ...

theoncologist.alphamedpress.org/content/19/11/1156.full

Nov 01, 2014 - Both improve the outcome of patients with metastatic colorectal cancer (mCRC) either as monotherapy or in combination with chemotherapy [8–11].

Author: Martha M. Kirstein

Published in: Oncologist - 2014

Authors: Martha M Kirstein · A Lange · Anne Prenzler · Michael P Manns · S Kubicka · Arndt V...